Navigation Links
Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
Date:3/2/2011

EAST BRUNSWICK, N.J., March 2, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the 31st Annual Cowen & Co. Health Care Conference, on Monday, March 7, 2011, at 1:00 p.m. Eastern Time.  The conference will be held at The Boston Marriott Copley Place in Boston, MA.  

A live webcast of the presentation can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
2. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
3. Savient Closes Sale of $230 Million in Convertible Senior Notes
4. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
5. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
6. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
7. Savient Pharmaceuticals Announces Search for CEO
8. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
10. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
11. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... LONDON , Feb. 27, 2017 This ... understand Teva and its partnering interests and activities since ... Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:2/28/2017)... 2017 Research and Markets has announced ... 2014-2025" report to their offering. ... The global digestive enzyme ... 2025. Growing consumer awareness regarding the severity of digestive disorders ... stimulate industry growth over the forecast period. The increasing incidence ...
(Date:2/28/2017)... ... Research and Markets has announced the addition of the "Orthobiologics ... The global orthobiologics market is expected to reach USD 10.2 ... predominantly driven by the increasing orthopedic disease and musculoskeletal disease burden ... of orthobiologics are presumed to accelerate the market demand over the ...
Breaking Medicine Technology:
(Date:2/28/2017)... Utah (PRWEB) , ... February 28, 2017 , ... ... held Overl.ai Inc., a healthcare automation intelligence company based in New York. , ... is ensuring the provider’s workflow remains unaltered. Those two fundamental reasons are the ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and overall body strength, which often leads to a host of health issues, ... of the American Geriatrics Society discovered that good overall muscle strength in ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear ... work for a company involved in the underground testing of nuclear weapons. Years later, ... Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... Morristown, New Jersey (PRWEB) , ... February 27, 2017 , ... ... the highest cancer rates, among all types and genders. And the need for advanced ... led by RWJ and its top-rated cancer care program, in collaboration with their non-profit ...
Breaking Medicine News(10 mins):